Sarcopenia: Again and Updated

Kutsal, Yeşim Gökçe

doi:10.31086/tjgeri.2020.131

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considered one of the major causes of frailty, sarcopenia is another geriatric syndrome that can cause adverse health outcomes in older adults with cancer older adults with cancer (4,5). Studies conducted on older adults have reported that sarcopenia occurs in 30.1% of gastric cancer patients (6), and in 15% of colorectal cancer patients (7).…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between Frailty and Sarcopenia in Older Adults With Cancer

SAĞLAM¹

2021

tjgeri

View full text Add to dashboard Cite

Introduction:The objective of this study was to determine the prevalence of and factors affecting frailty and sarcopenia and to investigate the relationship between these two conditions.Materials and Methods: This cross-sectional, descriptive study included 204 geriatric cancer patients who were admitted to the Chemotherapy Day Unit of a university hospital and who met the study's inclusion criteria. The Descriptive Characteristics Questionnaire, Modified Charlson Comorbidity Index, and Edmonton Frail Scale were used as data collection tools. A body composition analyzer, a hand dynamometer, a stopwatch, a stadiometer, and a tape measure were used to determine the presence of sarcopenia.Results: The prevalence of frailty was found to be 12.26%. The mean Edmonton Frail Scale score was significantly positively correlated with age and significantly negatively correlated with the number of years of education. It also had a significant relationship with gender and living-alone status. The prevalence of sarcopenia, on the other hand, was found to be 6.4%, and the presence of sarcopenia was found to be significantly related to age, livingalone status, and smoking status. The presence of sarcopenia significantly affected the level of frailty, increasing it 5.3-fold. Conclusion:Our study results reveal the importance of assessing older adults with cancer for geriatric syndromes and for determining their risk factors. To reduce the negative health outcomes and to provide individualized care, it is important to assess individuals in terms of frailty and sarcopenia before deciding on the treatment and care methods to employ.

show abstract

Section: Introductionmentioning

confidence: 99%

The Relationship Between Frailty and Sarcopenia in Older Adults With Cancer

SAĞLAM¹

2021

tjgeri

View full text Add to dashboard Cite

show abstract

“…Sarcopenia, which is defined as progressive loss in muscle mass and function in recent studies, has been found as the one of the most important factors affecting survival. [4] Sarcopenia is associated with increased morbidity and mortality for many cancer types such as pancreatic cancer, breast cancer, hepatocellular cancer, and renal cell carcinoma. [5][6][7][8] In the literature, up to %65 of pancreatic cancer cases, in particular, have been found associated with sarcopenia.…”

mentioning

confidence: 99%

Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma

basoglu¹

2022

EJMI

View full text Add to dashboard Cite

The patients with ampullary carcinomas are usually diagnosed at earlier stages due to the symptoms related to biliary obstruction. Ampullary cancer must be treated Objectives: Our aim is to investigate the prognostic value and effect on chemotherapy toxicity of pre-treatment sarcopenia determined with positron emission tomography/computerized tomography(PET/CT) in patients with ampullary carcinoma. Methods: Characteristics of patients retrieved retrospectively. Skeletal muscle area(SMA) measurement of the muscle at L3 vertebra level was evaluated for each patient from their PET/CT scan taken at the time of diagnosis. The sex-specific cut-off levels for determining sarcopenia were <38.5 cm2/m2 for females and <52.4 cm2/m2 for males. Association between oncological and radiological data was analyzed. Results: A total of 90 patients included in the study. Median age at diagnosis was 62(range: 44-77). Half of the patients were sarcopenic. Pre-treatment sarcopenia was determined as an independent variable predicting survival for both disease-free-survival(DFS) and overall survival(OS). Sarcopenic patients had statistically significant shorter OS(67.2 months for non-sarcopenic patients vs 53.2 months for sarcopenic patients, 95%CI:63.6-70.9, p<0.001), and a trend for shorter DFS(48 months for non-sarcopenic patients vs 36.8 months for sarcopenic patients, 95%CI:20.3-53.4, p=0.95) was also determined. On the other hand, chemotherapy related toxicity has also seen more in sarcopenic patients. Conclusion: Detecting the presence of pre-treatment sarcopenia may enable clinicians to predict the patient group with low survival and high probability of treatment toxicity. In order to protect this group of patients from toxicity, pretreatment sarcopenia measurement should be applied in routine practice and should guide treatment plan.

show abstract

Sarcopenia screening of community-dwelling individuals aged 65 and over within the primary care setting

Moore,

Gallagher

2024

PPR

View full text Add to dashboard Cite

BACKGROUND: The term sarcopenia, referring to declining function with age, has no universally agreed definition. Sarcopenia develops from multifactorial interactions, resulting in health problems such as frailty and increased falls risk; and for which screening may enable timely intervention. As sarcopenia screening equipment recommended by The European Working Group on Sarcopenia in Older People (EWGSOP2) is not always available in primary care, alternate screening strategies are needed. OBJECTIVE: To investigate the efficacy of the SARC-CalF questionnaire for sarcopenia screening in primary care and agreement between SARC-CalF and SARC-F questionnaires, with EWGSOP2 cut-off values. METHODS: Fifty community-dwelling adults aged 65yrs and over completed the SARC-CalF and EWGSOP2 strength and physical performance outcome measures. Calculations for probability of sarcopenia and skeletal muscle mass were completed. Agreement between operational definitions and outcome measures were assessed to establish screening accuracy. RESULTS: Prevalence of probable sarcopenia ranged from 10–48% depending on outcome measure; SARC-CalF increased prevalence by 55% compared to SARC-F. Questionnaires agreed more strongly with probable sarcopenia as measured by leg than grip strength. Gait speed agreed significantly with strength and physical performance measures. CONCLUSIONS: In community-dwelling adults aged 65yrs and over, outcome measure used influenced rates of probable sarcopenia. Within primary care, equations may enable assessment of muscle mass, while formulae may enable assessment of the probability of sarcopenia. Gait speed is recommended for quantification of sarcopenia severity.

show abstract

Sarcopenia: Again and Updated

Cited by 3 publications

References 31 publications

The Relationship Between Frailty and Sarcopenia in Older Adults With Cancer

The Relationship Between Frailty and Sarcopenia in Older Adults With Cancer

Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma

Sarcopenia screening of community-dwelling individuals aged 65 and over within the primary care setting

Contact Info

Product

Resources

About